GlassScriptPhysician profile
Curtis R Gapinski
NPI 1184945024
$1,336.18
in general payments reported to CMS, 2019-2025
26 companies · $563 in 2025
The $563 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $204 · 2024: $569 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217.64 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.18 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $140.75 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $115.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.95 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $78.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $69.50 | 2024-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Novo Nordisk INC | $68.84 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Inspire Medical Systems, INC. | $54.10 | 2024-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $41.83 | 2023-2024 | Spravato |
| Amgen INC. | $30.72 | 2024-2025 | Otezla, Repatha, Repatha |
| Dynavax Technologies Corporation | $27.43 | 2024-2025 | Heplisav-B |
| Biogen, INC. | $26.15 | 2025 | Spinraza |
| Xeris Pharmaceuticals, INC. | $21.75 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.07 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.24 | 2024 | Rexulti |
| Grifols USA, LLC | $19.75 | 2024 | Prolastin-C Liquid |
| Verity Pharmaceuticals INC. | $18.14 | 2025 | Tlando |
| Harmony Biosciences LLC | $18.00 | 2024 | |
| Edwards Lifesciences Corporation | $17.57 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sobi, INC | $16.30 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.51 | 2023 | Quviviq |
| Astellas Pharma US INC | $15.44 | 2024 | Veozah |
| Exact Sciences Corporation | $14.46 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $14.46 | 2025 | |
| Impel Pharmaceuticals INC. | $14.27 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Gapinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.